Fruitflow Science and Cardiovascular Platelet Aggregation Prevention
Provexis (LSE:PXS) plc has made significant operational progress in scaling the international commercial footprint of Fruitflow®, its patented, natural cardiovascular functional food ingredient. Admitted to trading on AIM and a constituent of the FTSE AIM All-Share index, the life sciences company specializes in heart health ingredients. Extracted from water-soluble tomato concentrate, Fruitflow is scientifically proven and clinically validated to inhibit blood platelet hyperactivity without disrupting normal blood clotting cascades, helping maintain healthy blood circulation and cardiovascular health.
Landmark EFSA Health Claim and Commercial Alliances with DSM
A fundamental commercial asset for Provexis is Fruitflow's proprietary European Food Safety Authority (EFSA) Article 13.5 health claim, which confirms that water-soluble tomato concentrate helps maintain normal platelet aggregation, contributing to healthy blood flow. Under a long-standing worldwide Supply and distribution agreement with global nutrition giant dsm-firmenich, Fruitflow is sold to functional beverage makers, dietary supplement Brand owners, and medical nutrition corporations in over thirty countries worldwide.
Strategic Expansion Across China via BYHEALTH Partnership
The primary growth catalyst for Provexis (LSE:PXS) centres on its major strategic collaboration with BYHEALTH, China's premier consumer healthcare and dietary supplement enterprise. Following extensive clinical evaluations and regulatory filing with Chinese food safety regulators, BYHEALTH has commenced commercial distribution of co-branded Fruitflow cardiovascular supplements across retail pharmacy multiples and digital E-commerce channels in mainland China, representing a transformative multi-year Volume expansion opportunity.
Financial Trajectory, Revenue Expansion, and Operating Leverage
In its audited annual results for the year ended 31 March 2026, Provexis (LSE:PXS) reported substantial revenue growth driven by expanding direct commercial sales of Fruitflow powder and rising Royalty revenues. Operational gross margins have benefited from high-volume Manufacturing agreements, while administrative expenses remain tightly controlled. The company does not currently pay a dividend, prioritizing Capital deployment toward commercial inventory management, intellectual property maintenance, and corporate Debt reduction.
Regulatory Dynamics and Upcoming Strategic Milestones
Provexis (LSE:PXS) operates in international nutraceutical sectors where consumer education and regulatory dietary claim substantiation are vital. Over the next twelve months, key milestones include monitoring commercial inventory re-order rates from BYHEALTH in China, concluding additional direct brand distribution partnerships in Europe and North America, and publishing interim financial accounts confirming continued progress toward sustainable operational profitability.
Sector Context and Market Backdrop
Platelet aggregation, the clumping of blood platelets, is part of normal blood clotting but is also linked to cardiovascular events. Fruitflow, a water-soluble tomato concentrate, has been studied for its effect on platelet function, and it holds a health claim from the European Food Safety Authority, a regulatory milestone that is relatively rare for food ingredients. A claim of this kind gives brand owners confidence to market products with clear health messages in Europe.
What to Watch Next
Readers may follow the commercial alliance with DSM, the Partnership with BYHEALTH in China and the use of Fruitflow in functional beverages and supplements. Filtration and processing steps affect the consistency of the ingredient, which is important for formulation. Revenue from licensing and ingredient supply will indicate how the global footprint is developing, and the company's updates on new territories and product launches show how the science is being brought to consumers.






Please wait processing your request...